PMID- 15928736
OWN - NLM
STAT- MEDLINE
DCOM- 20050920
LR  - 20101118
IS  - 0022-9032 (Print)
IS  - 0022-9032 (Linking)
VI  - 62
IP  - 4
DP  - 2005 Apr
TI  - Kinetics of chemokines in acute myocardial infarction.
PG  - 301-14; discussion 315-6
AB  - BACKGROUND: Chemokines are supposed to play an important role in the activation 
      of monocytes and in the development of atherosclerosis. There are also 
      suggestions that chemokine-mediated enhanced coagulability may be related to the 
      pathogenesis of acute coronary syndromes.Aim. To assess the kinetics of 3 
      chemokines: Monocyte Chemoattractant Protein-1 (MCP-1), Macrophage Inflammatory 
      Protein-1alfa (MIP-1alpha) and Regulated on Activation Normal T cell Expressed 
      and Secreted (RANTES) in patients with ST-elevation myocardial infarction 
      (STEMI). METHODS: The study group consisted of 40 patients (pts) with STEMI who 
      were divided into 2 groups -- 16 pts with anterior MI (AMI) and 24 pts with 
      inferior or lateral MI (IMI). According to the type of received therapy, the pts 
      were divided into 2 other groups: group A -- 30 pts treated with thrombolytic 
      agents or primary angioplasty and group B -- 10 pts without recanalisation 
      therapy. The control group consisted of 10 healthy volunteers. Blood samples for 
      MCP-1, MIP-1alpha and RANTES serum levels was taken on admission and 3 h, 24 h, 
      48 h, 72 h and 7 days afterwards. RESULTS: The baseline MCP-1 and RANTES levels 
      were significantly higher in pts with STEMI than in controls (1068.9 vs 880.9 
      pg/ml, p<0.05; 50.8 vs 33.9 pg/ml, p<0.005). In pts with STEMI, peak levels of 
      MCP-1 and MIP-1alpha were significantly higher 3h than 24h from admission (MCP-1 
      1274.4 vs 1097.4 pg/ml, p<0.02; MIP-1alpha 39.2 vs 22.0 pg/ml, p<0.01). In all 
      STEMI pts there was a positive correlation between MIP-1alpha 3h and left 
      ventricular ejection fraction (LVEF) (r=0.455, p<0.05) and a negative correlation 
      between MIP-1alpha 3h and LV end-diastolic diameter (LVEED) (r=-0.453, p<0.05). A 
      significant positive correlation between TnI level and chemokines in both AMI and 
      IMI patients was detected, being the highest in AMI and IMI groups when 
      MIP-1alpha 24 h and TnI were compared (R=0.852, p<0.003 and R=0.646, p<0.0001). 
      In pts with IMI, a positive correlation between RANTES, MIP-1alpha 3h and LVEF 
      was found (R=0.322, p<0.03 and R=0.399, p<0.008). In group A, all MIP-1alpha 
      values were significantly higher than in group B. Also, peak MIP-1alpha levels 
      significantly differed between groups A and B (44.8 vs 8.3 pg/ml, p<0.006). In 
      pts from group B, a negative correlation between MCP-1 measured an admission and 
      LVEF was found (R=-0.690, p<0.05). CONCLUSIONS: We found a significant elevation 
      of chemokines in the early period of acute MI. The correlations between different 
      parameters suggest, that chemokines may serve as new parameters of immune 
      activation in STEMI and also may play the dominant role in the cardiac 
      inflammatory response and subsequent repair processes.
FAU - Kobusiak-Prokopowicz, Malgorzata
AU  - Kobusiak-Prokopowicz M
AD  - Department of Cardiology, Medical Academy, Wroclaw, Poland.
FAU - Orzeszko, Jacek
AU  - Orzeszko J
FAU - Mazur, Grzegorz
AU  - Mazur G
FAU - Mysiak, Andrzej
AU  - Mysiak A
FAU - Orda, Alina
AU  - Orda A
FAU - Mazurek, Walentyna
AU  - Mazurek W
LA  - eng
LA  - pol
PT  - Journal Article
PL  - Poland
TA  - Kardiol Pol
JT  - Kardiologia polska
JID - 0376352
RN  - 0 (CCL2 protein, human)
RN  - 0 (Chemokine CCL2)
RN  - 0 (Chemokine CCL3)
RN  - 0 (Chemokine CCL4)
RN  - 0 (Chemokine CCL5)
RN  - 0 (Macrophage Inflammatory Proteins)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Angioplasty, Balloon, Coronary
MH  - Case-Control Studies
MH  - Chemokine CCL2/*blood
MH  - Chemokine CCL3
MH  - Chemokine CCL4
MH  - Chemokine CCL5/*blood
MH  - Female
MH  - Humans
MH  - Macrophage Inflammatory Proteins/*blood
MH  - Male
MH  - Middle Aged
MH  - Myocardial Infarction/*blood/drug therapy/physiopathology/*therapy
MH  - Thrombolytic Therapy
MH  - Time Factors
EDAT- 2005/06/02 09:00
MHDA- 2005/09/21 09:00
CRDT- 2005/06/02 09:00
PHST- 2005/06/02 09:00 [pubmed]
PHST- 2005/09/21 09:00 [medline]
PHST- 2005/06/02 09:00 [entrez]
PST - ppublish
SO  - Kardiol Pol. 2005 Apr;62(4):301-14; discussion 315-6.